Tradestie Institutional Equity Comparison Engine
ZYME vs NUVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZYME Overall Edge
ZYME Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zymeworks Inc. (ZYME) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ZYME trades at 55.0x Forward P/E with 22.6% operating margin (+828.7% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, ZYME sits in CONSOLIDATION (45th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ZYME
ZYME 55.0x vs NUVB N/M Fwd P/E
Growth & Margin Winner
ZYME
Op Margin 22.6% vs -61.2% ยท YoY +828.7% vs +242.6%
Momentum & Technical Winner
ZYME
1Y +15.7% vs -46.9% ยท 52W Pos 44% vs 2%
Options & Structure Winner
ZYME
CONSOLIDATION (45th %ile IV) vs BREAKDOWN (26th %ile IV)
ZYME
NASDAQ
Zymeworks Inc.
Pharmaceutical Preparations
$26.14
-2.68% 1D
Market Cap
$1.9B
1M Return
-8.09%
1Y Return
+15.66%
Forward P/E
55.0x
Unified AI Score
59.5 / 100
HOLD
Tech 60.0
Fund 59.0
Flow 67.0
Mom 50.0
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ZYME +15.66%
NUVB -46.85%
Spread: +62.51 pp (ZYME Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZYME Revenue | NUVB Revenue | ZYME Op. Margin | NUVB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | $40M | N/A | -481.3% | N/A | ZYME |
| FY2021 | $30M | N/A | -808.2% | N/A | ZYME |
| FY2022 | $410M | N/A | 31.6% | N/A | ZYME |
| FY2023 | $80M | N/A | -181.6% | N/A | ZYME |
| FY2024 | $80M | $10M | -179.7% | -7527.3% | ZYME |
| FY2025 | $110M | $60M | -87.3% | -338.7% | ZYME |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZYME | NUVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $1.3B | Larger Scale | ZYME |
| Trailing P/E Ratio Valuation | 50.7x | N/M | Lower Multiple | ZYME |
| Forward P/E Ratio Valuation | 55.0x | N/M | Lower Multiple | ZYME |
| Revenue Growth (YoY) Growth | +828.7% | +242.6% | Higher Growth | ZYME |
| Operating Margin (TTM) Profitability | 22.6% | -61.2% | Higher Margin | ZYME |
| Net Profit Margin Profitability | 16.3% | -67.4% | Higher Margin | ZYME |
| Return on Equity (ROE) Capital Efficiency | 15.0% | -49.1% | Higher ROE | ZYME |
| 52-Week Range Position Momentum | 44% ($22โ$32) | 2% ($4โ$10) | Stronger Trend | ZYME |
| Beta / 30D Volatility Risk Regime | 0.87ฮฒ ยท 56% Vol | 1.52ฮฒ ยท 55% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 59.5 / 100 (HOLD) | 61.0 / 100 (BUY) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ZYME vs NUVB Buy Guide
ZYME
CONSOLIDATION
56d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
45th %ile
IV Regime
Balanced (25thโ60th %ile)
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ZYME nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.